Elixicure reported on Monday that its Elixicure CBD-infused pain relief products has received US Food and Drug Administration (FDA) over-the-counter drug registration certification following a successful year-long process.
The announcement was made by the company's chief of business development, Yaniv Kotler.
To date, this registration and certification marks the very first and currently the only, Over-The-Counter (OTC) Topical drug with Cannabidiol (CBD), revealed the company.
According to the company, Elixicure is an all-natural, non-addictive pain relief cream developed to help reduce inflammation, swelling, aches and pains. The product contains Cannabidiol (CBD) extract, one of the main active chemical compounds naturally found in the hemp plant and contributing to the beneficial medicinal qualities of hemp. Unlike THC, hemp CBD extract does not make you feel "high".
In conjunction, the company's Elixicure is manufactured by Honest Globe, developers of luxury cosmetic, health and beauty products. The products are made with naturally-derived ingredients, using certified industry-standard manufacturing processes.
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP